FORM OF SERIES A COMMON STOCK PURCHASE WARRANT PLUS THERAPEUTICS, INC.Plus Therapeutics, Inc. • August 14th, 2024 • Surgical & medical instruments & apparatus
THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Plus Therapeutics, Inc., a Delaware corporation (the “Company”), up to ________________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
AMENDMENT AND RESTATEMENT OF THE PLUS THERAPEUTICS, INC. SERIES B COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • August 14th, 2024 • Plus Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This Amendment and Restatement (this “Amendment”), dated as of August 9, 2024 (the “Effective Date”), is made and entered into by and between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Series B Common Stock Purchase Warrant to purchase up to [•] shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $[•] per share, originally issued by the Company to the Holder on May 9, 2024 (the “Warrant”).
AMENDMENT AND RESTATEMENT OF THE PLUS THERAPEUTICS, INC. SERIES A COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • August 14th, 2024 • Plus Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
This Amendment and Restatement (this “Amendment”), dated as of August 9, 2024 (the “Effective Date”), is made and entered into by and between Plus Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Series A Common Stock Purchase Warrant to purchase up to [•] shares of the Company’s common stock, par value $0.001 per share, at an exercise price of $[•] per share, originally issued by the Company to the Holder on May 9, 2024 (the “Warrant”).
